// App-Quantinova.ai

: Time to Improvement in Daily Signs and Symptoms Associated With Atopic Dermatitis (AD) in Patients With Moderate-to-Severe AD in Pooled Monotherapy Studies of Abrocitinib

Researchers

Presenter

  • Melinda J Gooderham

Principal Investigators

  • Mark G Lebwohl

  • Eric L Simpson

  • Andreas Wollenberg

  • Andrew G Bushmakin

  • Joseph C Cappelleri

  • Marco DiBonaventura

  • Ricardo Rojo

  • Melissa Watkins

  • Hernan Valdez

  • Daniela E Myers

Medical Centers

  • SKiN Centre for Dermatology, Peterborough, ON, Canada

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Oregon Health and Science University, Portland, OR

  • Ludwig Maximilian University, Hautklinik LMU München, Munich, Germany

  • Pfizer, Groton, CT

  • Pfizer Inc, New York, NY

  • Pfizer Inc, Collegeville, PA

Locations

  • United States

  • Canada

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

Disease

  • Atopic Dermatitis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03349060

  • NCT03575871

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved